According to our (Global Info Research) latest study, the global Modified Live Vaccine market size was valued at US$ 552 million in 2025 and is forecast to a readjusted size of US$ 826 million by 2032 with a CAGR of 6.8% during review period.
In 2025, global Modified Live Vaccine approximately 22,364 k doses, with an average global market price of around US$ 24 per dose. Gross margin is about 47%. The cost is 13 usd. The Production is about 25,000 k doses. A Modified Live Vaccine is a type of live vaccine made from a pathogen that has been weakened or genetically modified to reduce its ability to cause disease while retaining limited replication capability. After administration, it can mimic natural infection and stimulate strong and long-lasting immune responses in animals. Modified live vaccines are widely used in disease prevention for swine, cattle, sheep, poultry, and companion animals. Compared with inactivated vaccines, they usually provide stronger and faster immunity with lower doses, but they require stricter control over storage, transportation, safety, and strain stability.
Modified live vaccines will develop toward improved safety, stability, and precision. As large-scale farming and animal disease prevention requirements continue to increase, manufacturers will focus more on attenuation stability, control of reversion-to-virulence risk, duration of immunity, and cross-protection capability. Genetic attenuation, reverse genetics, vector-based vaccines, and multivalent combination vaccines will become important R&D directions, enabling broader protection against multiple pathogens or serotypes and improving immune efficacy across swine, cattle, sheep, poultry, and companion animals. At the same time, cold-chain stability, freeze-drying processes, and mass administration methods such as spray, drinking water, and intranasal delivery will continue to improve, reducing vaccination costs and increasing efficiency in large-scale applications.
This report is a detailed and comprehensive analysis for global Modified Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Modified Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Modified Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Modified Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Modified Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Modified Live Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Modified Live Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zoetis, Ceva Santé Animale, Boehringer Ingelheim Animal Health, MSD Animal Health, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, IDT Biologika, Vaxxinova, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Modified Live Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monovalent Live Attenuated Vaccines
Multivalent Live Attenuated Vaccines
Combination Live Attenuated Vaccines
Market segment by Pathogen
Viral Live Attenuated Vaccines
Bacterial Live Attenuated Vaccines
Parasitic Live Attenuated Vaccines
Market segment by Application
Livestock
Poultry
Companion Animals
Others
Major players covered
Zoetis
Ceva Santé Animale
Boehringer Ingelheim Animal Health
MSD Animal Health
Virbac
HIPRA
Vetoquinol
Phibro Animal Health
IDT Biologika
Vaxxinova
KBNP Inc.
China Pharmaceutical Group Animal Health Co., Ltd.
Jinyu Bio-technology Co., Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Modified Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Modified Live Vaccine, with price, sales quantity, revenue, and global market share of Modified Live Vaccine from 2021 to 2026.
Chapter 3, the Modified Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Modified Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Modified Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Modified Live Vaccine.
Chapter 14 and 15, to describe Modified Live Vaccine sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Modified Live Vaccine. Industry analysis & Market Report on Modified Live Vaccine is a syndicated market report, published as Global Modified Live Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Modified Live Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.